Agios Pharmaceuticals, Inc.
AGIO Healthcare Biotechnology
Agios Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $54.0 million, up 48.0% from fiscal 2024. In the quarter to June 2026, revenue grew 259.3%, EPS grew 12.4% and free cash flow grew 25.0%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow AGIO
Agios Pharmaceuticals, Inc. (AGIO) Altman Z-score
Agios Pharmaceuticals, Inc.'s Altman Z-score for fiscal 2025 is 8.12, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 8.12 | (0.73) |
| FY2024 | 8.85 | 4.55 |
| FY2023 | 4.30 | (1.58) |
| FY2022 | 5.88 | 5.25 |
| FY2020 | 0.63 | (3.51) |
| FY2019 | 4.15 | (2.79) |
| FY2018 | 6.94 | 3.03 |
| FY2017 | 3.90 | 1.28 |
| FY2016 | 2.62 | (15.90) |
| FY2015 | 18.52 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.66 | — | 0.80 | |
| Retained earnings / total assets | (0.43) | — | −0.61 | |
| EBIT / total assets | (0.36) | — | −1.20 | |
| Market value of equity / total liabilities | 15.16 | — | 9.09 | |
| Sales / total assets | 0.04 | — | 0.04 | |
| Altman Z-score | Safe zone | 8.12 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 12.52 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| IMNM Immunome, Inc. compare | 21.6× |
| ZYME Zymeworks Inc. compare | 11.6× |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 8.4× |
| AGIO Agios Pharmaceuticals, Inc. | 8.1× |
| MESO Mesoblast Limited compare | 3.4× |
| MRVI Maravai LifeSciences Holdings, Inc. compare | 0.4× |
| SRPT Sarepta Therapeutics, Inc. compare | −1.0× |
| PVLA Palvella Therapeutics, Inc. compare | −11.5× |
| MLYS Mineralys Therapeutics, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets